Omalizumab for the Treatment of Bullous Pemphigoid: A Single Center Experience

Öz

Bullous pemphigoid is the most common bullous dermatosis seen in elderly population and accompanied by many comorbidities. Since immunoglobuline-E (Ig-E) antibodies play an important role in the pathogenesis of the disease, omalizumab targeting Ig-E proposes an effective and safe profile. In this study, we aimed to evaluate the efficacy and safety of omalizumab in bullous pemphigoid patients. Nineteen patients who received omalizumab treatment for at least 3 months with the diagnosis of bullous pemphigoid were included in the study. All patients had at least 1 comorbid condition, the most common being hypertension (79.0%) and type 2 diabetes mellitus (68.4%). The mean number of omalizumab treatments was 7.0±2.9. With omalizumab treatment, complete response was achieved in 11 (57.9%) of the patients and partial response was achieved in 8 (42.1%). The initial systemic steroid dose could be reduced in all patients with a complete response. All patients tolerated omalizumab without side‐effects. In conclusion, omalizumab is an effective and safe treatment option that reduces the need for systemic corticosteroids in patients with older age and multiple comorbidities. Further large-scale and prospective studies are needed to evaluate the efficacy of omalizumab in the treatment of bullous pemphigoid.

Anahtar Kelimeler

• Omalizumab
• bullous pemphigoid
• immunoglobulin-E

Büllöz Pemfigoid Tedavisinde Omalizumab: Tek Merkez Deneyimi

Öz

Büllöz pemfigoid yaşlı popülasyonda en sık görülen ve birçok komorbiditenin eşlik ettiği büllöz dermatozdur. İmmünoglobulin-E (Ig-E) antikorları hastalığın patogenezinde önemli bir rol oynadığından, Ig-E'yi hedef alan omalizumab etkili ve güvenli bir profil göstermektedir. Bu çalışmada büllöz pemfigoid hastalarda omalizumabın etkinlik ve güvenilirliğini değerlendirmeyi amaçladık. Çalışmaya büllöz pemfigoid tanısıyla en az 3 ay omalizumab tedavisi alan 19 hasta dahil edildi. Hastaların tamamında en az bir eşlik eden hastalık mevcuttu; en sık görüleni hipertansiyon (%79.0) ve tip 2 diyabet (%68.4) idi. Ortalama omalizumab tedavi sayısı 7.0±2.9 idi. Omalizumab tedavisi ile hastaların 11 (%57.9) 'inde tam yanıt, 8 (%42.1)'inde kısmi yanıt elde edildi. Tam yanıt alınan tüm hastalarda başlangıç sistemik steroid dozu azaltılabildi. Tüm hastalar omalizumabı yan etki olmaksızın tolere etti. Sonuç olarak omalizumab ileri yaş ve çoklu komorbiditeleri olan hastalarda sistemik kortikosteroid ihtiyacını azaltan etkili ve güvenli bir tedavi seçeneğidir. Omalizumabın büllöz pemfigoid tedavisinde etkinliğini değerlendirmek için daha büyük ölçekli ve prospektif çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

• Omalizumab
• büllöz pemfigoid
• immunoglobulin-E

Kaynakça

1. 1. Amber KT, Valdebran M, Kridin K, Grando SA. The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease. Front Med (Lausanne). 2018;5:201.
2. 2. Sadik CD, Schmidt E. Resolution in bullous pemphigoid. Semin Immunopathol. 2019;41:645-54.
3. 3. D'Aguanno K, Gabrielli S, Ouchene L, Muntyanu A, Ben-Shoshan M, Zhang X, et al. Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of Efficacy and Safety. J Cutan Med Surg. 2022;26:404-13.
4. 4. Nagel A, Lang A, Engel D, Podstawa E, Hunzelmann N, de Pita O, et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol. 2010;134:320-30.
5. 5. Kowalski EH, Kneibner D, Kridin K, Amber KT. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev. 2019;18:526-34.
6. 6. Ling X, Shou X, Lou Y, Ling J, Zhang M, Yu T, et al. Research progress of omalizumab in the treatment of bullous pemphigoid. J Dermatol. 2023;50:575-587.
7. 7. İncel Uysal P, Yalçın B, Öktem A. Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid. TURKDERM. 2017;51(4):124-8.
8. 8. Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134:465-69.

9. 9. Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol. 2004;122:1091-95.
10. 10. Castel M, Alexandre M, Jelti L, Pham-Ledard A, Viguier M, Bédane C, et al. Updated French guidelines for the therapeutic management of bullous pemphigoid. Ann Dermatol Venereol. 2022;149:81-91.
11. 11. Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123:704-5.
12. 12. Dopp R, Schmidt E, Chimanovitch I, Leverkus M, Brocker EB, Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol. 2000;42:577-83.
13. 13. Ishiura N, Fujimoto M, Watanabe R, Nakashima H, Kuwano Y, Yazawa N, et al. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci. 2008;49:153-61.
14. 14. Balakirski G, Alkhateeb A, Merk HF, Leverkus M, Megahed M. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature. J Eur Acad Dermatol Venereol. 2016;30:1778-82.
15. 15. Lonowski S, Sachsman S, Patel N, Truong A, Holland V. Increasing evidence for omalizumab in the treatment of bullous pemphigoid. JAAD Case Rep. 2020;6:228-33.
16. 16. Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71:468-74.
17. 17. Vassallo C, Somenzi A, De Amici M, Barruscotti S, Brazzelli V. Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid. Dermatol Ther. 2022;35:e15946.
18. 18. Velin M, Dugourd PM, Sanchez A, Bahadoran P, Montaudié H, Passeron T. Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study. J Eur Acad Dermatol Venereol. 2022;36:e539-e42.
19. 19. Alexandre M, Bohelay G, Gille T, Le Roux-Villet C, Soued I, Morin F, et al. Rapid disease control in first-line therapy-resistant mucous membrane pemphigoid and bullous pemphigoid with omalizumab as add-on therapy: a case series of 13 patients. Front Immunol. 2022;13:874108.
20. 20. Aguado Vázquez Á, Estébanez Corrales A, Melgosa-Ramos FJ, Mascaró Galy JM, Fulgencio-Barbarin J, Bosch Amate X, et al. Efficacy of Omalizumab for the treatment of Bullous Pemphigoid. Spanish multicenter real-world experience. Clin Exp Dermatol. 2024:llae067.
21. 21. Chebani R, Lombart F, Chaby G, Dadban A, Debarbieux S, Viguier MA, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol. 2024;190:258-65.
22. 22. Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66:479-85.
23. 23. Chuang KW, Hsu CY, Huang SW, Chang HC. Association Between Serum Total IgE Levels and Clinical Response to Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2023;11:2382-9.e3.
24. 24. Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73:705-12.
25. 25. Asero R. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders? Eur Ann Allergy Clin Immunol. 2021;53:47-8.
26. 26. Straesser MD, Oliver E, Palacios T, Kyin T, Patrie J, Borish L, et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2018;6:1386-8.e1.